2026 Interim report
Filed with HKEX · Stock code 2697 · · 53 pages · English
Summary by 6ix AI
The report includes sections on management discussion, R&D and product pipeline, and financial review, providing insights into the company's strategic direction and market position. It highlights the company's core product, a percutaneous puncture surgical robot, and outlines ongoing research and development efforts aimed at expanding its applications. The report also discusses future plans, including the development of new products and enhancements to existing technologies, emphasizing the company's commitment to innovation in minimally invasive surgical solutions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Guangdong True Health Medical Technology Development Co. Ltd. on 6ix
Earlier from Guangdong True Health Medical Technology Development
- Announcement of final offer price and allotment results
- List of Directors and their Roles and Functions
- Documents on Display
- PHIP (1st submission)
Later from Guangdong True Health Medical Technology Development
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary Announcement on Significant Progress in Research on Extracorporeal Liver Perfusion Support Therapy Using an Organ Perfusion System
- Announcement Of Passing Away Of Joint Company Secretary, Authorised Representative And Process Agent
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- Appointment of joint company secretary, authorized representative and process agent and waiver from strict compliance with rules 3.28 and 8.17 of the listing rules
Follow Guangdong True Health Medical Technology Development into a list and get an email when it puts out news.
Follow Guangdong True Health Medical Technology Development